FIELD: pharmaceuticals, medicine.
SUBSTANCE: disclosed is ophthalmologic composition containing alpha-2-adrenergic agonist such as 5-bromo-6(2-imidazolin-2-yl-amino)-quinoxaline as therapeutically active component in amount of at most 01451 at pH 7.0 or higher and solubility enhancing component representing carboxymethyl cellulose in amount effective for alpha-2-adrenergic agonist solubility enhancing.
EFFECT: effective therapeutic action of active component; decreased adverse effect on patient.
8 cl, 1 dwg, 4 tbl, 3 ex
